Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Abstract

The management of congenital adrenal hyperplasia due to 21-hydroxylase (CYP21) deficiency requires glucocorticoid substitution with oral hydrocortisone given twice or thrice daily. In paediatric practice little is known of the bioavailability of oral hydrocortisone tablets used in these patients. The aim of this study was to assess the bioavailability of oral hydrocortisone and to evaluate current replacement therapy in the light of cortisol pharmacokinetic properties.We determined the bioavailability of hydrocortisone following oral and intravenous administration in sixteen (median age: 10·9 years, range: 6·0-18·4 years) adequately controlled CYP21 deficient patients. Serum total cortisol concentrations were measured at 20-min intervals for 24 h while patients were on oral substitution therapy, and at 10-min intervals for 6 h following an intravenous bolus of hydrocortisone in a dose of 15 mg/m 2 body surface area. The area under the serum total cortisol concentration versus time curve (AUC) following oral and intravenous administration of hydrocortisone was calculated using the trapezoid method. The bioavailability was estimated by dividing the corrected for dose AUC after oral hydrocortisone administration by the corrected for dose AUC after the intravenous hydrocortisone administration and was exemplified as a percentage. After oral administration of hydrocortisone in the morning, median serum total cortisol concentrations reached a peak of 729·5 nmol/l (range: 492-2520 nmol/l) at 1·2 h (range: 0·3-3·3 h) and declined monoexponentially thereafter to reach undetectable concentrations 7 h (range: 5-12 h) after administration. Following administration of the evening hydrocortisone dose, median peak cortisol concentration of 499 nmol/l (range: 333-736 nmol/l) was attained also at 1·2 h (range: 0·3-3·0 h) and subsequently declined gradually, reaching undetectable concentrations at 9 h (5-12 h) after administration of the oral dose. After the intravenous hydrocortisone bolus a median peak serum total cortisol concentration of 1930 nmol/l (range: 1124-2700 nmol/l) was observed at 10 min (range: 10-20 min). Serum cortisol concentrations fell rapidly and reached undetectable levels 6 h after the hydrocortisone bolus. The absolute bioavailability of oral hydrocortisone in the morning was 94·2% (90% confidence interval (CI): 82·8-105·5%) whereas the apparent bioavailability in the evening was estimated to be 128·0% (90% CI: 119·0-138·0%).We conclude that the bioavailability of oral hydrocortisone is high and may result in supraphysiological cortisol concentrations within 1-2 h after administration of high doses. The even higher bioavailability in the evening, estimated using as reference the data derived from the intravenous administration of hydrocortisone bolus in the morning, is likely to reflect a decrease in the hydrocortisone clearance in the evening. Decisions on the schedule and frequency of administration in patients with congenital adrenal hyperplasia should be based on the knowledge of the bioavailab...

Serum Cortisol and 17-Hydroxyprogesterone Interrelation in Classic 21-Hydroxylase Deficiency: Is Current Replacement Therapy Satisfactory?

“…That the peak negative correlation between the two hormones was observed earlier during the nighttime (at lag time 20 min) than during the daytime (at lag time 60 min) suggests that 17OHP suppression is achieved sooner after hydrocortisone administration during the nighttime, and provides further evidence of decreased HPA axis activity between 1600 -0400 h. Thus, the pattern of 17OHP secretion and the cortisol-17OHP interrelation along with knowledge of the main pharmacokinetic properties of the oral hydrocortisone formulation used (26,27) may allow us to make appropriate decisions about the dose and administration schedule of hydrocortisone replacement therapy.…”

Metabolic evaluation of young women with congenital adrenal hyperplasia

“…However, if this replacement does not correctly meet individual physiological requirements, patients can develop either hyperandrogenism or hypercortisolism. The former can lead to early puberty, short stature, high lean mass and infertility, while the latter may lead to short stature, insulin resistance, osteoporosis, high fat mass and obesity (2)(3).…”

Ritmo de crescimento de crianças com hiperplasia congênita da supra-renal em tratamento com baixas doses de hidrocortisona

“…Uso irregular da medicação, durante o período de estudo, foi informado por 20% das crianças, mas este número pode ser ainda maior. A biodisponibilidade da Hc oral é praticamente completa e permitiria um controle adequado com ingestão a cada 8h em doses apenas 6% maiores que uma aplicação correspondente IV (15). No entanto, as dificuldades de adesão acabam propiciando períodos de "escape" durante as 24hs, suficientes para estimular o ACTH e, conseqüentemente, a produção androgênica.…”